“Even after the COVID-19 pandemic has subsided, clinical trial participants may grow accustomed to virtual or home health visits, and be hesitant to participate in more traditional, often travel-heavy, study processes to which the industry is accustomed,” Robey states.

“PharPoint has anticipated this shift for some time and is ready to advise sponsors on how to navigate the evolving FDA regulations while effectively moving to remote monitoring, tele-visits, home health visits, ePRO, eCOA, and eSource. These approaches directly speak to PharPoint’s flexibility. We’re able to run virtual trials through our existing procedures while offering a consultative, team-building approach.”